BFM
CHRS icon

Boothbay Fund Management’s Coherus Oncology CHRS Stock Holding History

Boothbay Fund Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.4K Hold
15,287
– – ﹤0.01% 2156
2026
Q1 		$25.8K Sell
15,287
-4,001
-21% -$7.11K ﹤0.01% 1955
2025
Q4 		$27.4K Hold
19,288
– – ﹤0.01% 1866
2025
Q3 		$31.6K Buy
19,288
+5,910
+44% +$6.57K ﹤0.01% 1807
2025
Q2 		$9.78K Hold
13,378
– – ﹤0.01% 1405
2025
Q1 		$10.8K Hold
13,378
– – ﹤0.01% 1348
2024
Q4 		$18.5K Sell
13,378
-6,840
-34% -$7.67K ﹤0.01% 1421
2024
Q3 		$21K Hold
20,218
– – ﹤0.01% 1547
2024
Q2 		$35K Sell
20,218
-1,046
-5% -$2.1K ﹤0.01% 1433
2024
Q1 		$50.8K Sell
21,264
-79,880
-79% -$197K ﹤0.01% 1468
2023
Q4 		$337K Sell
101,144
-96,222
-49% -$258K 0.01% 1143
2023
Q3 		$738K Buy
197,366
+182,366
+1,216% +$842K 0.02% 892
2023
Q2 		$64K Buy
+15,000
New +$88.5K ﹤0.01% 1664
2020
Q1 		– Sell
-12,000
Closed -$222K – 873
2019
Q4 		$216K Sell
12,000
-20,747
-63% -$383K 0.02% 690
2019
Q3 		$663K Sell
32,747
-1,678
-5% -$33.5K 0.06% 401
2019
Q2 		$761K Buy
+34,425
New +$598K 0.07% 332

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Boothbay Fund Management's CHRS Position: Q2 2026 in Review

Boothbay Fund Management held its Coherus Oncology (CHRS) position steady in Q2 2026 at 15,287 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

Boothbay Fund Management first reported a position in CHRS in Q2 2019 and has held it in 16 quarters since. The position peaked at $761K in Q2 2019. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Boothbay Fund Management held 15,287 shares of Coherus Oncology worth $21.4K as of Q2 2026.
  • Boothbay Fund Management left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2156 holding.
  • Boothbay Fund Management first reported a position in Coherus Oncology in Q2 2019 and has held it in 16 quarters since.
  • Boothbay Fund Management's Coherus Oncology position peaked at $761K in Q2 2019.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.